Q3 EPS Forecast for Fate Therapeutics Increased by Analyst

Fate Therapeutics, Inc. (NASDAQ:FATE) – Stock analysts at Leerink Partnrs raised their Q3 2025 EPS estimates for shares of Fate Therapeutics in a research note issued to investors on Wednesday, September 3rd. Leerink Partnrs analyst D. Graybosch now anticipates that the biopharmaceutical company will earn ($0.28) per share for the quarter, up from their prior estimate of ($0.37). The consensus estimate for Fate Therapeutics’ current full-year earnings is ($1.63) per share. Leerink Partnrs also issued estimates for Fate Therapeutics’ Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($1.13) EPS, FY2026 earnings at ($1.10) EPS, FY2027 earnings at ($1.18) EPS, FY2028 earnings at ($0.90) EPS and FY2029 earnings at ($0.82) EPS.

Several other research analysts have also issued reports on the stock. Robert W. Baird cut their target price on shares of Fate Therapeutics from $5.00 to $4.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 14th. Barclays lowered their target price on shares of Fate Therapeutics from $10.00 to $2.00 and set an “overweight” rating for the company in a report on Wednesday, May 14th. Wells Fargo & Company lowered their target price on shares of Fate Therapeutics from $4.00 to $2.50 and set an “equal weight” rating for the company in a report on Wednesday, August 13th. Needham & Company LLC restated a “hold” rating on shares of Fate Therapeutics in a report on Thursday, June 12th. Finally, Wall Street Zen upgraded shares of Fate Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, August 18th. One investment analyst has rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $3.30.

Fate Therapeutics Stock Up 3.8%

Shares of NASDAQ FATE opened at $1.01 on Friday. The firm has a market cap of $116.48 million, a PE ratio of -0.70 and a beta of 2.21. Fate Therapeutics has a 12-month low of $0.66 and a 12-month high of $4.20. The company’s fifty day simple moving average is $1.11 and its 200 day simple moving average is $1.12.

Fate Therapeutics (NASDAQ:FATE) last posted its quarterly earnings data on Tuesday, August 12th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.06. Fate Therapeutics had a negative net margin of 2,025.05% and a negative return on equity of 50.95%. The company had revenue of $1.91 million for the quarter, compared to analyst estimates of $1.16 million.

Institutional Investors Weigh In On Fate Therapeutics

Hedge funds have recently bought and sold shares of the stock. Savant Capital LLC bought a new stake in Fate Therapeutics during the second quarter valued at approximately $27,000. Bridgeway Capital Management LLC bought a new stake in Fate Therapeutics during the second quarter valued at approximately $28,000. CWM LLC lifted its position in Fate Therapeutics by 899.6% during the first quarter. CWM LLC now owns 41,435 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 37,290 shares during the last quarter. Graham Capital Management L.P. bought a new stake in Fate Therapeutics during the fourth quarter valued at approximately $37,000. Finally, Brevan Howard Capital Management LP bought a new stake in Fate Therapeutics during the fourth quarter valued at approximately $41,000. 97.54% of the stock is currently owned by institutional investors.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.